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Abstract: Assisted Reproductive Technologies (ARTs) have revolutionised reproductive 
medicine; however, reports assessing the effects of ARTs have raised concerns about  
the immediate and long-term health outcomes of the children conceived through ARTs. 
ARTs include manipulations during the periconceptional period, which coincides with an 
environmentally sensitive period of gamete/embryo development and as such may alter 
cardiovascular development and health of the offspring in postnatal life. In order to  
identify the association between ARTs and cardiovascular health outcomes, it is important 
to understand the events that occur during the periconceptional period and how they are 
affected by procedures involved in ARTs. This review will highlight the emerging evidence 
implicating adverse cardiovascular outcomes before and after birth in offspring conceived 
through ARTs in both human and animal studies. In addition, it will identify the potential 
underlying causes and molecular mechanisms responsible for the congenital and adult 
cardiovascular dysfunctions in offspring whom were conceived through ARTs. 
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In recent years, the use of Assisted Reproductive Technologies (ARTs) have increased rapidly as a 
result of increasing infertility rates in humans and increasing demand for the reproduction of livestock 
with desired genetic characteristics. There are, however, a range of controversial issues surrounding  
in vitro embryo culture and embryo transfer, both of which are important processes in ARTs. These 
processes occur during the periconceptional period and are known to involve manipulation of the nutritional 
environment. Hence, to understand the link between ARTs and their effects on cardiovascular health, 
we need to understand and address these major questions: 
(1) When is the periconceptional period? 
(2) Why is the periconceptional period a critical window of embryonic development? 
(3) What are the different procedures involved in ARTs and how do these impact the 
periconceptional environment? 
(4) What is the evidence that the periconceptional environment influences cardiovascular health in 
fetal life and in adulthood? 
(5) What is the evidence that ARTs influence cardiovascular health before and after birth? 
(6) What are the most likely mechanisms linking ARTs and risk of cardiovascular disease in fetal 
and adult life? 
2. When Is the Periconceptional Period? 
ARTs involve manipulations that occur during oocyte maturation, fertilization and preimplantation, 
each of which is part of the periconceptional period and are likely to involve changes in the nutritional 
environment during this period [1,2].The term “periconceptional” is defined as the period before and 
immediately after the time of conception and is a critical period during early development [3]. Most 
human studies have included different time frames in defining the periconceptional period and these 
depend on the specific research questions (Figure 1). For example, a study of maternal multivitamin 
supplementation in the periconceptional period on congenital abnormalities, included from one month 
prior to conception to about two months after conception [4]. Another study investigating the effect of 
periconceptional maternal characteristics on embryonic development has defined 14 weeks prior to 
conception as the periconceptional period [5]. 
Similar to human studies, animal studies have used different timings around conception to define the 
periconceptional period (Figure 1). For example, the periconceptional period is defined as 3–6 days before 
and 1 day after conception in one study and 3.5 days before and after conception in another study in 
mice (term, 19 days) [6,7]. In rats (term, 21 days), the periconceptional period is defined as 3 weeks prior 
to and 5 days after conception, whereas in another study, it is defined as 4.25 days after conception [8,9]. 
In sheep (term, 145–150 days), different definitions of the periconceptional period have been used to 
investigate the impact of maternal nutrition in the periconceptional period on the development and health 
of the offspring (Figure 1). The Auckland model defines the periconceptional period as extending from 
60 days prior to conception until 30 days gestation (term, 145 days) [10,11]. This period includes oocyte 
maturation, preimplantation and postimplantation of the embryo as well as early placentation [12], 
because implantation occurs on day 16 of gestation in sheep [12]. The Nottingham model includes the 
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period between day 0 till day 30 of gestation (term, 147 days), which covers embryo/blastocyst development, 
preimplantation development of the embryo and the period of implantation [13]. A commonality 
between these models is that the period of intervention extends beyond the periconceptional period to 
the postimplantation period and thus includes processes such as development of the uterine glands  
which provide nutrition (uterine histotroph) to the developing embryo and the process of placentation [14] 
Thus extension into the postimplantation period may not provide evidence of changes that are specific 
to manipulations during oocyte maturation and embryo development [15]. In contrast, the Adelaide 
model is restricted to the critical windows of oocyte maturation and preimplantation embryo 
development (60 days prior conception to 7 days after conception; term, 150 days) [16]. Similarly,  
the Southampton model also includes 15 days before until 15 days after conception (term, 147 days), 
which includes oocyte maturation and blastocyst formation [17].Therefore, isolating the impact of 
perturbations during oocyte maturation and the preimplantation period alone from those of the 
postimplantation and placentation periods [18–20]. 
 
Figure 1. Different models of the periconceptional period in studies in humans, rodents and 
ruminants include different stages of oocyte and embryo development. Note: Implantation 
occurs at different days after conception across species (Human, 7–9 days; Rodents, 6–7 days; 
Sheep 16 days) [4–10,13,16,17]. 
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3. Why Is Periconceptional Period a Critical Window of Development? 
3.1. Oogenesis Occurs Early in Life 
A women’s reproductive function is determined in fetal life because the specialized cells known  
as primordial germ cells (PGCs), that give rise to gametes, are present within the wall of the yolk sac at 
4–6 weeks gestation [21–23]. PGCs migrate from the yolk sac to the genital ridge between 6 and 
12 weeks gestation and differentiate into oogonia after becoming invested by somatic support cells [21]. 
By 12 weeks gestation, oogonia commence the first meiotic prophase and are called primary oocytes. 
Immediately after this, they become dormant in the early diplotene stage [23]. When the nuclei of these 
primary oocytes enlarge and become watery, the primary oocytes are known as germinal vesicles. The 
primary oocyte, surrounded by a single layered, squamous capsule of epithelial follicles is the primordial 
follicle [24]. At ~5 months gestation, the pool of these follicles reaches its peak of ~7 million, however, 
most of these follicles degenerate and the maximum number of oocytes a female will have in her lifetime 
is set at birth, ranging from 700,000 to 2 million [25,26], with only 400,000 follicles remaining at 
puberty [23,25]. Any changes in the maternal nutritional environment such as under- or overnutrition 
can affect oogenesis and other reproductive functions and hence can have an impact on the 
granddaughter’s reproductive health [27–30]. Studies have also shown that nutritional manipulations 
during pregnancy can have transgenerational effects, since they not only alter cardiovascular outcomes 
in the offspring but can also result in cardiovascular dysfunction and alter glucose and insulin control in 
the next generation [31–34]. Thus, in addition to understanding the impact of ARTs on the 
cardiovascular health of the offspring, it will be of interest to understand the impact on the grandchildren. 
During and after puberty, hormonal secretions from the hypothalamus, anterior pituitary gland and 
ovary regulate the menstrual cycle, which averages 28 days in humans, 17 days in sheep and 4–5 days 
in rodents [35–38]. A small group of primordial follicles are converted into primary follicles with a decrease 
in inhibitory signals and/or an increase in stimulatory factors which remain largely unknown [39–41]. 
The granulosa cells undergo a squamous to cuboidal epithelial morphology from primordial to primary, 
and then several layers of granulosa cells begin to develop to form secondary follicle and the theca  
cells emerge in the transition from primary to secondary follicle [23,40]. A thick glycoprotein layer 
surrounds the surface of the oocyte known as zona pellucida [42]. Some of these follicles degenerate, 
but a few enlarge in response to rising levels of follicle stimulating hormone (FSH) and develop a fluid 
filled cavity known as the antrum from fluid generated by granulosa cell secretions and by plasma 
transudate (antral follicle) [43,44]. Eventually, one of the antral follicles becomes dominant (mature 
Graafian follicle), while the others degenerate [41]. At ~13–14 days of the menstrual cycle in humans, 
the primary oocyte resumes meiosis under the influence of the ovulatory surge of luteinizing 
hormone (LH) caused by positive feedback of estrogen, produced by the dominant follicle, on the 
pituitary gland and hypothalamus [23]. At the end of the first meiotic division, a small polar body 
containing a set of chromosomes is released into the perivitelline space [24]. Then the oocyte progresses 
to the second meiotic division, where it is again arrested in metaphase ~3 h before ovulation. Follicular 
rupture and ovulation occurs ~38 h after the beginning of the ovulatory surge [23]. The oocyte then 
moves into the ampulla of the oviduct and remains viable for fertilization for 24 h. Fusion of the sperm 
enables the oocyte to resume meiosis [45]. At the end of the second meiosis, the oocyte divides into two 
Nutrients 2015, 7 1382 
 
 
unequal cells: a polar body and the female pronucleus. The sperm loses its nuclear envelope, undergoes 
chromatin decondensation and replacement of the sperm specific protamine by histones. The DNA from 
the sperm binds to the histones in the oocyte and is surrounded by a new nuclear envelope of maternal  
origin, which forms the male pronucleus. The fusion of the pronuclei of sperm and oocyte results in a 
zygote [46]. Perturbations during oocyte maturation, such as those that may occur during parts of ART 
(ovarian hyperstimulation, in vitro maturation and in vitro fertilization (IVF)) have been shown to reduce 
the quality of oocytes and embryo viability as well as alter energy metabolism of the oocytes [47,48]. 
This has been shown to result in delayed embryonic development, increased abnormal blastocyst 
formation, fetal growth retardation, increased fetal loss, congenital malformations, imprinting disorders, 
and a range of postnatal growth and development disorders such as poor cognitive development, increased 
risk for neurological problems, cardiovascular diseases and respiratory tract infections [47,49–54].  
In addition, superovulation can also perturb proper placental and fetal development by altering 
trophoblast differentiation and distribution of cell types in the placenta [55]. 
3.2. Key Events in Embryonic Development during the Periconceptional Period in Different Species 
Studies in humans and animals have shown that nutritional manipulations during blastocyst 
formation, such as culturing the embryo in media, have been associated with cleavage anomalies, 
improper embryo development, an altered placental transcriptome, fetal and birth defects, increased 
blood pressure, vascular dysfunctions, poor neuromotor development, behavioural disorders and 
imprinting disorders [56–63]. In addition, the maturation of endometrium in human also takes place 
before implantation and studies have shown that ovarian stimulation could alter endometrial receptivity 
and impair implantation rate [64,65]. There is variation between species in the timing of ovulation after 
the beginning of estrous, completion of the second cleavage, hatching from the zona pellucida and 
implantation [66]. The steps from fertilization to implantation of the embryo include several major 
processes such as decondensation of parental genomes and cleavage to blastomere formation which 
includes an equal first cleavage (2 cell), and subsequent asynchronous division resulting in 4, 8, 16,  
32 cell stages; (Table 1) [23,46]. With the development of a fluid filled cavity by the process of 
compaction, a blastocyst is formed [23]. The inner cell mass of the blastocyst will give rise to the embryo, 
the yolk sac, amnion and allantois while the outer cell mass develops into the chorion. As the hydrostatic 
pressure of the fluid increases within the cavity of the blastocyst, it expands and the zona pellucida  
is digested by enzymes which allow hatching of the embryo. This is followed by implantation of the 
embryo in the uterine wall (Table 1). 
3.2.1. Humans 
Ovulation occurs in the middle of the menstrual cycle i.e., around the 14th day of the cycle [67].  
After fertilization, the formation of 2 cell (first cleavage), 4 cell, 8 cell and 16 cell (morula) stages take 
place at 24, 40, 50, 72 h, respectively. By the 5th day, the blastocyst is formed, followed by zona hatching 
at 5–7 days and implantation at 7–9 days (Table 1). 
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Table 1. Timing of important events in the periconceptional period in relation to  
ovulation [66,68,69]. 
Timing of events during the 
periconceptional period Human Mouse Rat Sheep 
Time between ovulations 28 days 4–5 days 4–5 days 17 days 
Time to 2 cell stage (first cleavage) 24 h 21–23 20.6 h 24–26 h 
Time to 4 cell stage 40 h 38–50 72 h 30–36 h 
Time to 8 cell stage 50 h 50–60 78 h 42–45 h 
Time to 16–32 cells (morula stage) 72 h 60–70 84 h 63–86 h 
Formation of blastocyst 5 days 3–4 days 4–5 days 5–6 days 
Zona hatching 5–7 days 3.5 6 days 8 days 
Implantation 7–9 days 4–5 days 6–7 days 16 days 
Zygotic gene activation 40–50 h 24 h 24 h 30–45 h 
3.2.2. Rats 
Ovulation in rats and mice occurs after the first two stages (proestrus and estrus) of estrous cycle, 
which is ~10 h after the start of estrus [70,71]. The embryo divides to form the 4 cell stage (second 
cleavage) by 38–50 h in mice and 72 h in rats, which is at a later time point than in humans. The 
blastocyst is formed at around 3–4 days in mice and 4–5 days in rats followed by hatching at day 3–3.5 
in mice and at day 6 in rats. Implantation occurs at days 4–5 in mice and 6–7 in rats [72,73] (Table 1). 
3.2.3. Sheep 
Ovulation occurs 20–30 h after the beginning of estrus [35]. After the fertilization, the first cleavage 
division occurs 24 h after ovulation (Table 2), followed by the 4, 8 and 16 cell stages at 30–36 h, 42–45 h 
and 63–86 h, respectively. The formation of the blastocyst occurs between 5 and 6 days after ovulation 
in sheep [12,74]. Hatching takes place at day 8, so that elongation can occur prior to implantation at 
day 16 [12]. 
3.3. Zygotic Gene Activation Occurs during Early Embryogenesis 
One of the major events after fertilization is the transition of control of the developmental program 
of the zygote/embryo from maternally derived transcripts and proteins accumulated in the oocyte during 
the process of oogenesis to embryonic transcripts and proteins [75]. This transition is known as zygotic 
gene activation or embryonic gene activation [76]. Zygotic gene activation is associated with three main 
functions: (i) to degrade maternally inherited transcripts; (ii) to replace the oocyte specific transcripts 
that are common to both the oocyte and early embryo with zygotic transcripts; and (iii) to promote the 
generation of novel embryo specific transcripts by reprogramming the pattern of gene expression [68]. 
In humans and sheep the maternal-zygotic transition occurs between 4–8 cell stage and 8–16 cell stage 
respectively and is associated with the developmental loss of totipotency and in mice and rats, this occurs 
by the 2 cell stage (Table 1) [77]. The initiation of zygotic transcription also coincides with demethylation 
during embryogenesis, which is an important event in epigenetic programming that can affect chromatin 
structure and gene expression [78]. Nutritional manipulations such as culturing embryos in various 
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media have been shown to delay the transcription of important growth factors such as platelet-activating 
factor-receptor in mouse preimplantation embryos, which can affect the viability of the embryo [79]. 
Studies have shown that IVF has differential effects on growth factors by either delaying the first onset 
of expression of some of growth factors after the activation of zygotic genome or by decreasing the 
expression, which can hamper proper embryogenesis in mice [80]. 
Table 2. Assisted Reproductive Technologies (ARTs) and manipulations during 
oocyte/embryo development [81,82]. 
ART 
Treatment 
Infertility Treated Procedures Involved and Manipulation of Oocyte/Embryo Development 
IVF 
Blocked Fallopian tubes, 
endometriosis, 
unexplained infertility, 
ovarian failure,  
ovulatory disorders and 
male infertility 
Controlled ovarian hyperstimulation—Oocyte and follicular development 
Oocyte retrieval and transfer—Oocyte and follicular development 
Sperm retrieval and preparation—No direct effect on embryo 
In vitro fertilization—zygote 




endometriosis or  
unknown fertility 
Controlled ovarian hyperstimulation—Oocyte and follicular development 
Oocyte retrieval—Oocyte and follicular development 
Sperm retrieval and preparation—No direct effect on embryo 
ZIFT 
Severe male infertility, 
immunologic infertility or 
unexplained infertility 
Controlled ovarian hyperstimulation—Oocyte and follicular development 
Oocyte retrieval—Oocyte and follicular development 
Sperm retrieval and preparation—No direct effect on embryo 
In vitro fertilization—zygote 
In vitro embryo culture—zygote, cleavage 
AI and IUI Male infertility No direct effect on oocyte development 
ICSI Male infertility 
Controlled ovarian hyperstimulation—Oocyte and follicular development 
Oocyte retrieval—Oocyte and follicular development 
Sperm retrieval and preparation—No direct effect on embryo 
In vitro fertilization—Zygote 
In vitro embryo culture—Zygote, cleavage, morula, blastocyst 
Embryo transfer—Blastocyst 
AI, artificial insemination; GIFT, gamete intraFallopian transfer; ICSI, intracytoplasmic sperm injection; IVF, in vitro 
fertilization; IUI, intrauterine insemination. ZIFT, zygote intraFallopian transfer. 
3.4. Epigenetics Reprogramming Is an Important Event in Both Gametogenesis and Embryogenesis 
Epigenetics is defined as all meiotically and mitotically heritable changes in gene expression that 
occur without changes in the DNA sequence [83,84]. One of the main mechanisms involved is DNA 
methylation (other mechanisms involved are histone modifications such as acetylation, phosphorylation, 
methylation, ubiquitination and sumoylation) [85,86]. During mammalian development, gametogenesis 
and embryogenesis are the two critical periods where epigenetic reprogramming occurs (Figure 2) [87]. 
This begins with demethylation when PGCs migrate along the genital ridge followed by sex-specific 
pattern of remethylation before fertilization [88,89]. There is a second wave of whole genomic demethylation 
in the male pronucleus within hours of fertilization whereas the female pronucleus undergoes complete 
demethylation after several cleavage divisions [90]. During implantation, genome-wide methylation 
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takes place in a lineage-specific pattern [89]. However, there are certain genes, known as imprinted 
genes, that undergo erasure of methylation marks during PGC development and the methylation marks 
are re-established during gametogenesis but escape the second wave of demethylation that occurs after 
fertilization and thus maintain their methylation of CpG islands that was established during 
gametogenesis [91,92]. Imprinted genes are expressed differentially depending on their inheritance from 
maternal or paternal origin [93]. During development, one of the alleles of a particular gene is expressed 
only in the zygote and the other allele is silenced, and this process is known as genomic imprinting [87]. 
 
Figure 2. Epigenetic reprogramming during gametogenesis and embryogenesis. Adapted 
from [87,94]. 
This epigenetic reprogramming is essential for proper development because it controls expression of 
early embryonic genes, cell cleavage and cell determination [95]. Imprinted genes, in particular, play an 
important role in embryonic and fetal development as well as placental function [96–98]. Any defects 
during epigenetic reprogramming, including the imprinting process, may affect genotype and phenotype 
and are linked to embryonic abnormalities and diseases in later life [99]. As such, the periconceptional 
period, which involves the crucial process of epigenetic remodelling, makes the early oocyte or the 
preimplantation embryo vulnerable to perturbations that can have immediate and long-term consequences 
on the health of the offspring. For example, there is compelling evidence for a link between ARTs, 
manipulations in the periconceptional period, and epigenetic disorders (imprinting defects) [100].  
A recent study has also shown that maternal nutritional status during the periconceptional period was 
associated with persistent epigenetic changes at human metastable epialleles [101]. 
This section has provided evidence that the periconceptional period encompasses many important 
events that determine health of the embryo and that any manipulation during this period, such as ART, 
can impact the processes of oocyte maturation, embryogenesis, fetal and postnatal development. It is 
important to understand that different types of ARTs are being used and thus that each type of ART 
involves different manipulations to the periconceptional period. 
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4. What Are the Different Procedures Involved in ARTs and How Do These Impact the 
Periconceptional Environment? 
4.1. History, Procedures and Current Status of ARTs 
ARTs are manipulations during the periconceptional period in which the oocyte, sperm and/or zygote 
develop that apply laboratory or clinical techniques to gametes (sperm and ova) and/or embryos to 
establish pregnancy [102–104]. The history of ARTs dates back to 1890 when the first successful embryo 
transfer occurred in rabbits [105]. A live calf was successfully produced from embryo transfer 60 years 
later [106]. In 1973, two of the earliest human pregnancies occurred at the Queen Victoria Hospital in 
Melbourne but they lasted for less than a week [107]. These were chemical pregnancies identified by 
increasing plasma human chorionic gonadotropin (hCG) concentrations and provided the evidence that 
embryos produced from IVF could develop to the blastocyst stage and initiate implantation. The birth of 
the world’s first test-tube baby, Louise Brown, occurred on 25 July 1978 at Oldham hospital in England, 
UK [108,109]. This was a landmark in the area of reproductive medicine and paved the way for scientific 
developments to improve implantation and pregnancy rates. 
The use of ARTs has increased rapidly around the globe in recent years. In 2011, 588,629 treatment 
cycles were performed at clinics in 33 European countries, 151,923 cycles in the US and 66,347 cycles 
in Australia and New Zealand [110]. According to the European Society of Human Reproduction and 
Embryology, an estimated 5 million children have been conceived as result of ARTs [110]. The 
extensive usage of ARTs is attributed to increasing infertility rates in the population [111,112]. One of 
the reasons could be that women are considering pregnancy later in life. The average age of a first 
pregnancy has increased from 26.9 years in 1983 to 30.1 years in 2012 in Australia [113,114]. In 1991, 
around 23% of new mothers were aged over 30 years but this has risen to 37% in 2001 and 43% in 
2011 [115]. Similar trends were observed in the USA and Canada where the average age of women 
having their first child increased from 21.4 years in 1970 to 25.8 years in 2012 and from 23.5 in mid 
1960s to 28.1 in 2008, respectively [116,117]. There is evidence to suggest that fertility as well as 
fecundity declines with increasing age for both men and women [112,118–120]. Delayed child-bearing 
also results in increased time to conception and complications during pregnancy [121]. With recent 
advancements in both ARTs and clinical practice, coupled with the widespread availability of ART and 
improved success rates, there has been a rise in the number of couples that are experiencing problems 
with conception seeking treatment [122]. 
The improvements in ARTs have also benefited the livestock industry, which have resulted in great 
advancements in livestock production [123,124]. The introduction of reproductive technologies has 
increased production as well as reproduction of livestock animals with desired genetic 
characteristics [124,125]. They have also helped in overcoming reproductive problems, such as reducing 
generation intervals and preventing the spread of vertically transmitted diseases [126,127]. Livestock 
industries as a whole have scaled to new heights in terms of economic gains with the help of these 
reproductive technologies [125,128]. 
The most widely used ART is IVF because it has the highest success rate per cycle, irrespective of 
the cause of the infertility [81]. It was developed to treat infertility associated with blocked Fallopian 
tubes and to treat other disorders related to infertility such as endometriosis, unexplained infertility, 
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ovarian failure, ovulatory disorders and male infertility [129,130]. Gamete intraFallopian transfer 
(GIFT) and zygote intraFallopian transfer (ZIFT) were developed as alternative treatments to IVF in 
specific circumstances [82,131]. GIFT involves introduction of both egg and sperm in the Fallopian tube 
where fertilization and subsequent embryo development occurs [132–135]. GIFT treatment can be used 
as a treatment for sperm dysfunction, endometriosis or unknown infertility [136,137], but requires that 
at least one Fallopian tube is open. ZIFT involves removal of eggs followed by IVF with subsequent 
transfer of the embryo at the 2 cell stage into the Fallopian tube [138]. It can be used in cases of severe 
male infertility, immunologic infertility or unexplained infertility [138–141]. Other ARTs include 
artificial insemination (AI), intrauterine insemination (IUI) and intracytoplasmic sperm injection (ICSI), 
which are generally used in cases of male infertility and can be coupled with other ARTs, such as IVF, 
depending on the severity of the infertility (Table 2) [142,143]. 
4.2. Periconceptional Manipulations Associated with ARTs 
A typical IVF treatment involves administration of FSH for controlled ovarian hyperstimulation  
over several days to induce the development of multiple follicles and the maturation of oocytes is 
induced by administration of hCG. This is followed by aspiration of mature oocytes from the ovarian 
follicles and insemination with a prepared sperm sample in vitro. The zygote that forms after fertilization 
of the oocyte and sperm is cultured in a nutritional medium for either 2–3 days to form a cleavage stage 
embryo or 5–6 days to form a blastocyst, which is then transferred to the uterine cavity for implantation 
(Table 2) [144,145]. In the past, more than one embryo was transferred to increase the chance of 
pregnancy and this has been associated with multiple pregnancies [146]. Twin pregnancies are at an 
increased risk of premature birth and its associated complications [147,148]. Therefore, transfer of a 
single embryo has been advocated to reduce the risk of multiple pregnancies [149]. With the transfer of 
a single embryo, a desirable pregnancy rate with fewer multiple pregnancies has been achieved [150]. 
However, even with the transfer of a single embryo, there are reports of increased twinning [151]. 
4.3. In Vitro Embryo Culture: A Periconceptional Manipulation of the Nutritional Environment of the 
Gametes and/or Zygote Associated with ARTs 
An important component of many ARTs is the nutritional medium used for culturing the 
embryo [152,153]. The nutritional medium contains essential components required for optimal growth 
and to maintain the viability of the embryo at various stages of development [154]. The culture media 
from different clinics varies in composition but can be broadly classified into simple and complex 
media [155]. Simple culture medium includes Tryode’s, Earle’s T6, M16 and CZB, which contain 
balanced salt solutions and energy sources such as pyruvate, lactate and glucose. These are generally 
supplemented with serum from the patient or fetal cord serum because the media are known to lack of 
components that are essential for the growth and development of the embryo [156]. 
Efforts have been made to design media to match the dynamic in vivo environment and have led to 
the development of human tubal fluid (HTF) media [157]. HTF mimics the physiological environment 
of the human Fallopian tube and is based on the chemical composition of human tubal fluid [153,157]. 
The complex tissue culture medium contains amino acids, vitamins, nucleic acid precursors and metal 
ions and was originally designed to support somatic cells in culture, e.g., Ham’s F-10, MEM and  
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TCM-199 [155]. In recent years, media were designed with particular focus on each of the 
developmental stages of the embryo, broadly divided into pre-compaction and post-compaction stages 
or the cleavage and blastocyst stages [156]. 
The inclusion of human serum, which acts as a pH buffer and chelator for embryonic toxins such as 
“transitional and heavy metals” in addition to providing growth factors and nutrients such as amino acids 
and vitamins in the media, has been long debated [158–160]. The use of human serum in different culture 
media during the first 2 days of embryonic development in sheep leads to retarded growth but its 
inclusion during later stages leads to more blastocysts formations [161]. However, there are also reports 
of altered ultrastructure of the mitochondria and energy metabolism, epigenetic disorders including 
errors in imprinting, abnormal growth and gross abnormalities in several organ systems as a result of the 
addition of serum in the media during the early stages of embryonic development [162–165]. Recently, 
serum free culture media have been developed and proven to yield better results with increased 
blastocyst formation, higher implantation rates and reduced risk of contamination of the media by 
unknown components present in the serum [166,167]. 
We have described the complex maturation and developmental events of the oocyte and embryo that 
occur in the periconceptional period. These events must occur appropriately to allow gastrulation and 
the appropriate allocation of cells to each of the developing organ systems. We have also described the 
nutritional manipulations that the gametes and zygote are exposed to during the processes of ARTs 
(Table 2). Together, this information leads to questions about whether there is evidence that the 
periconceptional environment influences cardiovascular health as a fetus and into adulthood. 
5. What Is the Evidence that the Periconceptional Environment Influences Cardiovascular 
Health in Fetal Life and Adulthood? 
Cardiovascular disease is the leading cause of death worldwide causing an estimated 17.5 million 
deaths worldwide in 2012 and it is estimated to reach 23.3 million by 2030 [168,169]. Cardiovascular 
disease in adults is generally attributed to an unhealthy lifestyle during adulthood with most focus on 
poor diet, a sedentary lifestyle and smoking [170,171]. However, a growing body of evidence suggests 
that cardiovascular and metabolic disorders in adulthood may derive their origins from insults during 
prenatal life, including the periconceptional period [20,172]. Barker and colleagues coined the Fetal 
Origins of Health and Disease hypothesis, which stated that changes in the development of a permanent 
somatic structure or the “setting” of a physiological system by an early stimulus or insult during a critical 
period of development during which any manipulation of either environmental or nutritional factors can 
have long-lasting consequences on the physiology of the embryo and fetus [173,174]. 
Studies have shown that normal development of the mammalian cardiovascular system during the 
embryonic period as well as the transition from proliferative to hypertrophic cardiomyocytes growth 
during late gestation is dependent on the timely and accurate activation of many genes and signalling 
pathways [59,175]. Some of these signalling pathways are under epigenetic regulation such as DNA 
methylation and histone modifications [176,177]. Any abnormalities in the epigenetic control of these 
processes may result in cardiovascular malformation and susceptibility to disease in adult life [178,179]. 
The heart is comprised of cardiomyocytes and non-myocytes including fibroblasts, endothelial cells, 
mast cells, vascular smooth muscle cells and the surrounding extracellular matrix [180,181]. During the 
Nutrients 2015, 7 1389 
 
 
first two thirds of gestation, heart growth is predominantly due to proliferation of mononucleated 
cardiomyocytes [182]. In humans and sheep, cardiomyocyte maturation, characterised by quiescence 
(absence of cardiomyocyte cytokinesis), occurs in the last third of gestation and subsequently heart 
growth in late gestation and postnatal life is primarily through cardiomyocyte hypertrophy [183,184]. In 
sheep, cardiomyocyte quiescence is easily identified due to almost all mononucleated cardiomyocytes 
becoming binucleated and subsequently terminally differentiated by birth [175,185–187]. In humans, 
the majority of cardiomyocytes remain mononucleated, however, it is widely accepted that only a tiny 
proportion of mononucleated cardiomyocytes undergo cytokinesis/proliferation after birth [188,189]. 
Recent studies have also provided evidence that cardiomyocytes continue to proliferate until almost 
20 years of age [190]. In rodents, all cardiomyocytes are mononucleated at birth and retain the ability to 
proliferate and regenerate cardiac tissue after damage within the first week of life [191,192]. Like sheep, 
rodent cardiomyocytes become binucleated and terminally differentiated, however, unlike sheep and 
humans, this occurs rapidly between 4 and 12 days after birth [192–194]. Due to the limited potential 
for cardiomyocyte proliferation in postnatal life, the heart has a limited capacity to replace 
cardiomyocytes that are lost due to disease and aging. Subsequently, the number and the epigenetic 
profile of cardiomyocytes an individual is born with will have lifelong implications for cardiac health. 
Periconceptional Manipulations and Cardiovascular Disorders: Insights from Human  
and Animal Studies 
A series of epidemiological, clinical and experimental studies have shown that nutritional 
manipulations during the periconceptional period, may have adverse effects on cardiovascular health 
(Table 3) [59]. The most profound evidence was from the Dutch Winter Famine of 1944/45, which 
demonstrated that offspring exposed to malnutrition as an embryo or fetus during early gestation had 
elevated blood pressure in response to physiological stressors and 8.8% of those exposed during early 
gestation also had an increased risk of coronary heart disease compared to 0.9% and 2.5% of offspring 
whom were exposed to the famine in mid or late gestation respectively [195,196]. In another cohort 
periconceptional maternal tobacco smoking was associated with increased risk of congenital heart 
defects such as septal defects [197,198]. Likewise, alcohol consumption during the periconceptional 
period elevated conotruncal heart defects in offspring and that risk was associated with the frequency 
and the number of drinks consumed [199]. In a study examining the effects of the interaction of genetic 
factors and periconceptional nutritional manipulations on congenital heart defects, it was found that a 
low maternal dietary nicotinamide intake and usage of medicines such as antibiotics, anticonvulsants, 
anti-inflammatory, hormones and antimycotics during the periconceptional period independently 
increased the risk of congenital heart defects in the offspring by 2 fold [200]. 
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Table 3. Maternal undernutrition during the periconceptional period alters cardiovascular development. 













Undernutrition Early gestation ↑ [196] n/a n/a ↑ [195] n/a n/a n/a 
Alcohol consumption −30–+90 days n/a n/a ↑ [199] n/a n/a n/a n/a 
Low maternal dietary nicotinamide 
and exposure to a range of medicines 
−30–+60 days  n/a n/a ↑ [200] n/a n/a n/a n/a 
Rodent 
Protein restriction 0–4.25 days ↑ [201] n/a n/a n/a n/a n/a n/a 
Low protein diet 
−3.5–0 days ↑ [202] n/a n/a n/a n/a n/a ↓ 
0–3.5 days ↑ [203] n/a n/a n/a ↓ [203] n/a n/a 
Sheep Maternal undernutrition 
−60–7 days ↑ [204] n/a n/a n/a n/a n/a n/a 
1–30days ↔ [205] ↓[205] n/a n/a n/a n/a n/a 
0–95 days ↑ [206] ↓ [206] n/a n/a n/a n/a n/a 
−30–0 days n/a n/a n/a n/a n/a n/a ↓ [17] 
−15–15 days n/a n/a n/a n/a n/a ↑ [17] ↓ [17] 
1–31days ↑ [207] n/a n/a n/a ↑ [207] ↑ [207] n/a 
−61–30 days n/a n/a n/a n/a ↑ [11] n/a n/a 
−61–0 days n/a n/a n/a n/a ↓ [208] n/a n/a 
−61–30 days n/a n/a n/a n/a ↓ [208] n/a n/a 
−2–30 days n/a n/a n/a n/a ↓ [208] n/a n/a 
↑ = increase, ↓ = decrease, ↔ = no difference, n/a = not applicable (because not included in the reported study results). 
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Animal models have been useful in identifying the underlying mechanisms that are responsible for 
the association between nutritional manipulation in the periconceptional period and cardiovascular 
health in adult life (Table 3). Maternal protein restriction during the preimplantation period in rats 
resulted in a reduced number of cells in the blastocyst stage, a reduction in birth weight, accelerated 
postnatal growth and elevated systolic blood pressure (SPB) in postnatal life [201]. Maternal protein 
restriction, specifically during oocyte maturation, led to hypertension in the adult offspring [202]. 
Similarly maternal protein restriction from 0 to 3.25 days after mating reduced heart weight and 
increased SPB in offspring in postnatal life [203]. In addition, the heart to body weight ratio in females 
was negatively correlated with SBP measured at 9, 15, and 21 weeks [203]. 
In sheep, maternal undernutrition during the periconceptional period extending from 60 days prior to 
conception until 7 days after fertilization resulted in an increase in arterial blood pressure and rate 
pressure product in twins, but not singleton fetuses in late gestation (term, 150 days) [204]. There was 
altered baroreflex sensitivity in response to angiotensin II infusion at 1 year of age as a result of global 
energy restriction from the day of conception until 30 days of gestation [205]. Maternal undernutrition 
extending from 0 to 95 days gestation resulted in an increase in prefeeding basal blood pressure and 
blunted baroreflex in response to norepinephrine infusion at 3 years of age [206]. In another study 
undernutrition during the 30 days before conception resulted in diminished endothelium-dependent and 
independent vasodilatation in third order femoral arteries [17]. An undernutrition regime from  
15 days prior to until 15 days after conception resulted in greater vasoconstrictor responses in both left 
anterior descending coronary and left internal thoracic arteries [17]. There was attenuated  
endothelium-dependent and independent vasodilatation in third order femoral arteries as well as reduced 
endothelium-independent vasodilation in both the left anterior descending coronary and renal 
arteries [17]. There was an increase in blood pressure in response to frusemide, a loop diuretic used to 
activate renin angiotensin system, in 1.5 year old lambs of ewes that were undernourished between 1 
and 31 days of gestation. At 2.5 years, these lambs had increased interventricular septal wall thickness, 
mean left ventricular wall thickness and increased constriction to acetylcholine in isolated coronary 
arteries [207]. Furthermore, offspring born to ewes that were undernourished from −61 days before until 
30 days after conception had increased fetal heart weight relative to body weight in late gestation [11]. 
In contrast, relative heart weight was reduced in the offspring of ewes that were undernourished from 
60 days prior to conception, 60 days before and 30 days after conception and 2 days before and after 
conception [208]. 
The above studies provide evidence that nutritional manipulation in the periconceptional period has 
adverse effects on the cardiovascular system, which might predispose an individual to an increased risk 
of cardiovascular disease. 
6. What Is the Evidence that ARTs Influence Cardiovascular Health Before and After Birth? 
Studies have demonstrated that not only insults during the periconceptional period in vivo (Table 3), 
but also those that occur in vitro during this critical period of development can have detrimental effects 
on cardiovascular development [13,59,204,209,210]. This highlights the importance of understanding 
the long-term effects of ARTs on cardiovascular development. There are reports of altered fetal and postnatal 
growth and development as a result of in vitro nutritional manipulations during the periconceptional 
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period in humans, rodents, cows and sheep [211–213]. These reports have raised serious questions about 
the safety of ARTs for both the immediate and long-term health of individuals conceived through ARTs. 
Among the long-term health outcomes, cardiovascular health remains the most important concerns due 
to the sensitivity of heart development to perturbations during the periconceptional period [20,59,214,215]. 
A recent study reported the incidence of cardiac malformations using different search terms related 
to cardiac malformations and/or ARTs in the Medline database for the years 1999 to 2012. The search 
returned data on 32,000 births (21,000 naturally conceived; 11,000 conceived through ART) [216]. Cardiac 
malformations occurred in 1.8% (198 cases) of births conceived through ART compared to 0.4%  
(88 cases) of births in the general population [216]. Comparing the incidence of specific forms of 
cardiovascular disorders from a total of 11,000 pregnancies in ART children and 21,000 pregnancies in 
naturally conceived (NC) children respectively, there were 58 cases (0.53%) of atrial septal defect in 
ART vs. 26 cases (0.12%) in NC, 37 cases (0.34%) of changes in the interventricular septum in ART vs. 
18 cases (0.09%) in NC, 20 cases (0.18%) of coarctation of the aorta vs. 13 cases (0.06%) in NC, 18 cases 
(0.16%) of aortic stenosis in ART vs. 11 cases (0.05%) in NC, 11 cases (0.10%) of tetralogy of Fallot in 
ART vs. 5 cases (0.02%) in NC, 6 cases (0.05%) of stenosis of the pulmonary trunk in ART vs. 5 cases 
(0.02%) in NC and 48 cases (0.44%) of other non-specified cardiac defects in ART and vs 10 cases 
(0.05%) in NC. [216]. These data suggest that compared to natural conception, there is an increased risk 
of cardiovascular malformations in children conceived through ART. 
6.1. Congenital Heart Defects in Human Population 
Many studies have reported the incidence of congenital heart defects in children conceived through 
ARTs (Table 4). In the first report of a relationship between ART and congenital heart defects, Lancaster 
et al. found that there were 4 cases of transposition of the great arteries in the offspring conceived through 
IVF [217]. Several studies have also confirmed these findings. For example, a significant increase in 
overall congenital heart defects in children conceived through IVF compared to children with unassisted 
conception was reported in different population based studies [218–221]. The increase in cardiovascular 
defects also remained significant when the analysis was performed in only singletons [218,219]. Another 
population based study in Finland compared the risk of congenital defects in IVF and other ART 
categories with the control population based on infant sex and multi-fetal pregnancies and found an 
increase in congenital heart defects in the female offspring of singleton pregnancies in other ART 
categories group [222]. 
A case-control study using the California Linked Birth Cohort Dataset found an increased risk of 
major cardiac malformations in 4.8% of births from ART (IVF with or without ICSI, GIFT) compared 
to 3.0% in the matched control population [50]. After adjusting for maternal and infant factors such as 
maternal age, parity, race, multiple births, infant sex and year of birth, the rate of congenital heart defects 
was significantly higher in the infants born after ARTs [50]. When the heart defects in singleton and 
multi-fetal ART pregnancies were compared, the multi-fetal pregnancies had an increased risk of 
congenital cardiac defects than the singleton pregnancies [50]. An increased rate of congenital malformations 
in infants conceived by ART was also reported in a retrospective cohort study in Ottawa [223]. In a 
cross-sectional descriptive study in Iran, 8 cases of IVF pregnancies with congenital heart defects were 
reported in a population of 400 ART children [224]. 
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In addition to evidence that ARTs increase the risk of cardiac defects, studies have identified specific 
congenital cardiac defects associated with ARTs (Table 4). The prevalence of congenital heart 
malformations such as atrial septal defects and ventricular septal defects was four-fold higher in children 
born after IVF than the matched controls in a Finnish population based cohort study [225] In a  
cross-sectional study in Iran, children conceived through ARTs had increased risk of ventricular and 
septal defects [226]. A population based study analysed specific cardiovascular defects in the Danish 
population study and reported a significant increase in the prevalence of a single umbilical artery in IVF 
children when compared to controls [221]. In another population based, multicenter case controlled 
study of birth defects in the United States, the singleton births resulting from IVF and ICSI were at 
increased risk of septal heart defects, including ventricular septal defect, atrial septal defect and other 
non-specified defects compared to unassisted conception [227]. Using data from a Swedish database for 
the period 1982–2001, it was found that in addition to an overall risk of congenital heart diseases, the 
association between ARTs and congenital heart defects became more marked when the analysis was 
restricted to major cardiac defects such as common arterial trunk, double outlet right or left ventricle,  
D- and L-transposition of great vessels, double inlet left ventricle, endocardial cushion defect, tetralogy 
of Fallot, tricuspid atresia or stenosis, Ebstein’s anomaly, hypoplastic left heart syndrome, aortic valve 
atresia, specified anomalies of the great veins or to septal defects [228]. In another study, which used 
the Swedish database for the period 2001–2007 found an increased risk of cardiovascular malformations, 
which was similar to the data from the same database for the period (1982–2001) [229]. The study  
also reported an increased risk of septal and ventricular defects but the risk was lower during the period 
2001–2007 compared to the previous time period [229]. 
Based on a case-control study using data from Paris Registry of Congenital Malformations, it was 
found that cases of congenital heart diseases were more likely to be born as a result of ARTs when 
compared to controls [230]. The study investigated three major categories of congenital heart defects 
(all congenital heart diseases combined, congenital heart diseases without chromosomal abnormalities 
and congenital heart diseases without chromosomal abnormalities (excluding isolated ventricular septal 
defects)) and it was found that there was also a 40% increase in the overall risk of congenital heart 
disease without chromosomal abnormalities in infants conceived through ARTs after adjusting for 
maternal age, socioeconomic factors and year of birth [230]. Specific congenital malformations such as 
malformations of the outflow tracts and ventriculoarterial connections, cardiac neural crest defects and 
double outlet right ventricle were significantly associated with ARTs [230]. The study also reported that 
IVF and ICSI were associated with an increased risk of congenital heart disease, but not ovulation 
induction alone [230]. Another case–control study using data from the population-based Paris Registry 
of Congenital Malformations, and a prospective cohort study of congenital heart disease in children 
(EPICARD) investigated the association between ARTs and four specific forms of congenital heart 
diseases (hypoplastic left heart syndrome, transposition of great arteries, tetralogy of Fallot, and 
coarctation of the aorta) [231]. The study found that ARTs (IVF, ICSI and ovulation induction alone) 
were associated with a 2.4-fold increased risk of tetralogy of Fallot, after adjusting for maternal age, 
occupation, geographic origin, paternal age and year of birth [231]. There was no significant association 
between ART and the other 3 congenital malformations [231].  
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6.2. Evidence of Risk Factors for Long-Term Cardiovascular Outcomes in Humans 
The increased risk of cardiovascular defects at birth provides a strong justification for follow-up studies 
to investigate the effect of the procedures involved in ARTs on the long-term consequence on cardiovascular 
health outcomes. What is not known is whether ARTs are associated with an increased risk for clinical 
cardiovascular endpoints due to the young age of the ART population in humans. However, emerging 
studies have provided evidence for an association of ARTs with increased risk factors for cardiovascular 
disease (Table 5). 
Fetuses from ART pregnancies had altered cardiac morphometry and impaired systolic and diastolic 
function compared to controls [232]. When they were assessed during neonatal life, an increased 
diastolic blood pressure percentile, aortic and carotid intermedia thickness was reported in ART children 
compared to controls [232]. During infancy, children from ART pregnancies had increased right atrial 
size, right ventricular wall thickness, aortic wall thickness, SBP and heart rate as well as decreased 
shortening fraction, right sphericity index and systolic and diastolic function [232]. This evidence 
suggests that cardiovascular remodelling was present in fetal life and persisted into infancy in ART 
children and this may suggest an increased risk of cardiovascular disease in later life. 
A study has also shown that the children conceived through IVF had increased SBP and DBP at a 
mean age of 12.3 years [233]. Furthermore, there was an association between early childhood weight 
gain and SBP during follow-up [234], which is an important risk factor for cardiovascular disease in 
later life [235,236]. Similarly, in a cross-sectional study in Athens, a higher SBP and DBP deviation 
score was reported in ARTs children compared to naturally conceived children in the age group  
4–14 year [237]. 
Vascular functions were studied in ART conceived children at around 12 years of age and a ~25% 
reduction in flow-mediated dilation of the brachial artery evoked by reactive hyperemia was reported 
but no difference was observed with endothelium-independent vasodilation evoked by nitroglycerine [238]. 
This finding is suggestive of endothelial dysfunction in ART offspring, which is an important and early 
marker for the development of atherosclerosis in later life and has previously been shown to be present 
in healthy children whom were at increased risk of cardiovascular diseases [239–242]. The study also 
found a significant faster carotid femoral pulse wave velocity, which is widely used as a gold standard 
for measuring arterial stiffness as well as an increased carotid intima-media thickness, both of which are 
markers for development of atherosclerosis and independent risk factors for cardiovascular 
disease [238,243–245]. In addition, ART children had 30% higher pulmonary pressure at higher 
altitude [238]. The findings from this study provide evidence for both systemic and pulmonary vascular 
dysfunction in ART children, which could lead to adverse cardiovascular outcomes in later life [238]. 
Most importantly, it was reported that the vascular dysfunctions were not related to parental factors but 
more likely due to the ART procedure itself.
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Table 4. Congenital heart defects that result from ART. 
Study Type; Population; Year Sample Size (N) Congenital Heart Defects Reference 
Registry of IVF and GIFT 
pregnancies in Australia and 
New Zealand 
IVF-1694 4-cases of transposition of great arteries (p = 0.0034). [217] 
Population based study; 
Children conceived by IVF or 





- Increased cardiovascular defects among the infants conceived through IVF when compared with 
control children (p = 0.002) but no significant increase in cardiovascular defects in IUI infants. 
- Significant increase in cardiovascular defects was also reported when the analysis was done only 
in singletons (p = 0.003). 
[218] 
Population-wide cohort study; 
South Australian Perinatal 
Statistics Collection;  
January 1986–December 2002 
ART-6163  
Controls-302,811 
- There was significant association between the use of ARTs and risks of multiple cardiovascular 
defects for singleton births (1.8% vs. 1.2%; adjusted OR 1.36 (1.08–1.72)). 
- (Adjusted for maternal age, parity, fetal sex, year of birth, maternal race or ethnic group, maternal 
country of birth, maternal conditions in pregnancy, maternal smoking during pregnancy, 
socioeconomic status, and maternal and paternal occupation) 
[219] 






Increased prevalence of cardiovascular defects in children conceived with IVF, but not those 
conceived with ICSI compared to controls (p < 0.001). 
[220] 
Population based study; 
National professional Perinatal 




- Increased risk of overall cardiovascular malformations (OR 1.56, 95% CI 1.10–2.2). 
- After analysing specific cardiovascular malformations, an increased risk of single umbilical artery 
was reported (OR 1.93, 95% CI 1.11–3.35). 
(Adjusted for maternal age, parity and ethnicity) 
[221] 
Population based study; 
Medical Birth Register, 
Finland; 1996–1998 
IVF-4559  
Other ARTs-4467  
Controls-27,078 
- Increased risk of congenital heart defects in both IVF (p = 0.042) and ART categories (p = 0.021) 
compared to controls when expressed as prevalence of birth defects per 10,000 infants. 
- The singleton girls in other ART categories had an increased incidence of congenital heart defects 
when analysis was done for gender and multiplicity (adjusted OR 1.52, 95% CI 1.01–2.28). 
(Adjusted for age) 
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Table 4. Cont. 
Study Type; Population; Year Sample Size (N) Congenital Heart Defects Reference 
Case-control; California Patient 
Discharge Linked Birth Cohort 
Database Dataset; 2006 to 2007 
ART-4795  
Controls-46,025 
- Born after ARTs (adjusted OR 1.41, 95% CI 1.22–1.64). 
- The multi-fetal pregnancies were at increased risk of congenital cardiac defects compared to 
singleton (adjusted OR 1.56, 95% CI 1.31–1.85). 
(Adjusted for maternal and infant factors such as maternal age, parity, race, multiple births, infant sex 
and year of birth) 
[50] 
Retrospective cohort study: 




- Higher rate of congenital heart defects in infants conceived by ART than controls  
(adjusted OR 4.58, 95% CI 1.48–14.18). 
(Adjusted for maternal age, plurality, year of delivery, catchment area, gestational weight gain, parity, 
maternal smoking, medical history, Rh. negative, pelvic surgery) 
[223] 
Cross-sectional descriptive 
study; Royan Institute, Tehran; 
ART-400 8 cases (2%) of defects in cardiovascular system. [224] 
Population based cohort study; 
IVF Outpatient Clinic, 
University of Oulu and 
Infertility Clinic of the Family 
Federation of Finland and Oulu 
Controls- Finnish Medical 




4 fold increase in atrial septal and ventricular septal defects (OR 4.0, 95% CI 1.4–11.7). [225] 
Historical cohort study; Child 
Health and Development 
Research Centre;  
January 2008–December 2010 
ART-326  
Controls-652  
Increased risks of cardiovascular malformations in ART children (1.07% vs. 1.53%). [226] 
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Table 4. Cont. 
Study Type; Population; Year Sample Size (N) Congenital Heart Defects Reference 
Population based,  
multicenter case-control study, 
National Birth Defects 
Prevention Study;  
October 1997–December 2003 
Cases-9584  
(with birth defects)  
Controls-4792  
(no birth defects) 
- Increased risk of overall septal heart defects (ventricular septal defect, atrial septal defect and 
other non-specified defects) in singleton infants born after ART compared to unassisted 
conception (adjusted OR 2.1, 95% CI 1.1–4.0). 
- Increased risk of atrial septal defect secundum/ not otherwise specified defects (adjusted OR 3.0, 
95% CI 1.5–6.1), and ventricular septal defect plus atrial septal defect (adjusted OR 2.8, 95% CI 
1.2–7.0) in singleton infants compared to unassisted conception. 
(Adjusted for maternal age, study center, parity, family income and prematurity) 
[227] 
Population based study; 
Swedish Medical Birth 
Register, Swedish Registry of 
Congenital Malformations,  
and Swedish Hospital 
Discharge Register;  
1982–March 31, 2001 
ART-16,280  
Controls-2,039,943 
- An overall increased risk of congenital heart defects in infants conceived through ART was 
observed compared to controls; (adjusted OR 1.7, 95% CI 1.5–2.0). 
- A stronger association between ARTs and congenital heart defects when the analysis was 
restricted to major cardiac defects such as common arterial trunk, double outlet right or left 
ventricle, d- and l transposition of great vessels, double inlet left ventricle, endocardial cushion 
defect, tetralogy of Fallot, tricuspid atresia or stenosis, Ebstein’s anomaly, hypoplastic left heart 
syndrome, aortic valve atresia and specified anomalies of great veins  
(adjusted OR 2.1, 95% CI 1.6–2.8) or to septum defects in the absence of non-cardiovascular 
defects (adjusted OR 2.6, 95% CI 2.2–3.1). 
(Adjusted for year of birth) 
[228] 
Population based study; 
Swedish Medical Birth 
Register, Swedish Registry of 
Congenital Malformations,  
and Swedish Hospital 
Discharge Register;  
31 March 2001–1 January 2007 
IVF-15,570  
Controls-5,689,157 
- An overall increased risk of cardiovascular defects in infants conceived through ART was 
observed compared to controls (adjusted OR 1.30, 95% CI 1.13–1.49). 
- Compared to a previous study using the same database from 1982–2001, it was reported that both 
the studies had increased risk of atrial septal defects and ventricular septal defects  
(OR 3.16, 95% CI 2.71–3.67) vs. (OR 2.35, 95% CI 2.09–2.64). 
(Adjusted for year of birth, maternal age, parity, smoking, and body mass index) 
[229] 
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Table 4. Cont. 
Study Type; Population; Year Sample Size (N) Congenital Heart Defects Reference 
Case control study; Paris 
Registry of Congenital 
Malformations; 1987–2006 
Cases-5493  
(with congenital heart defects) 
Malformed controls-3487  
(malformations not previously 
associated with ART) 
- Cases from congenital heart diseases were more likely to be conceived through ARTs than other 
malformed controls (4.7% vs. 3.6%; p = 0.008). 
- Infants conceived through ART have 40% increase in the overall risk of congenital heart disease 
without chromosomal abnormalities. 
- Significant associations between ARTs and specific congenital malformations such as 
malformations of the outflow tracts and ventriculoarterial connections  
(adjusted OR 1.7, 95% CI 1.2–2.4) as well as cardiac neural crest defects and double outlet right 
ventricle (adjusted OR 1.7, 95% CI 1.1–2.7). 
(Adjusted for maternal age, geographic origin, occupation, and year of birth) 
[230] 
Case-control; Paris Registry of 
Congenital Malformations; 
1987–2009. Prospective cohort 
study, congenital heart disease 
in children (EPICARD);  
2005–2008 
Case-1583  
(with congenital heart defects) 
Malformed controls-4104  
(malformations not previously 
associated with ART) 
- ARTs were associated with a 2.4-fold increased risk of tetralogy of Fallot  
(adjusted OR 2.4, 95% CI 1.5–3.7). 
- No significant association between ART and hypoplastic left heart syndrome, transposition of 
great arteries and coarctation of the aorta malformations. 
(Adjusted for maternal age, occupation, geographic origin, paternal age and year of birth) 
[231] 
OR, odds ratio; CI, confidence intervals. 
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Table 5. Cardiovascular risk factors in fetal and postnatal life. 
Study Type; Population; Year Sample Size (N); Age(s) Cardiovascular Risk Factors Reference 
Prospective cohort study; 




28–30 weeks gestation,  
1 month,  
6 months 
- Fetuses (28–30 weeks gestation)—Increased left atrial area (1.48 vs. 1.35; p < 0.001), right atrial 
area (1.60 vs. 1.46; p < 0.001), interventricular wall thickness (2.7 vs. 2.4; p < 0.001) and right 
wall thickness (3.2 vs. 2.8; p = 0.038), decreased left (1.71 vs. 1.77; p = 0.003) and right  
(1.37 vs. 1.58; p < 0.001) ventricular sphericity indexes. 
- For systolic function, there was decreased left ejection fraction (63 vs. 69; p < 0.001), mitral ring 
displacement (4.2 vs. 4.7; p < 0.001), tricuspid ring displacement (5.5 vs. 6.5; p < 0.001), mitral 
systolic annular peak velocity (6 vs. 6.9; p = 0.038). 
- For diastolic function, there was decreased mitral ventricular inflow in early diastole 
displacement time (63 vs.73; p = 0.002), tricuspid ventricular inflow in early diastole 
deceleration time (51 vs. 64; p = 0.001), mitral annular peak velocity in early diastole (7 vs. 7.6; 
p = 0.049), tricuspid annular peak velocity in early diastole (8 vs. 8.3; p = 0.002) and isovolumic 
relaxation time (48 vs. 30; p = 0.003). 
- Neonates (1 month)—Increased DBP percentile (71 vs. 55; p = 0.042), aortic mean  
intima-media thickness (0.16 vs. 0.12; p = 0.011), aortic maximum intima-media thickness  
(0.19 vs. 0.14; p = 0.011), carotid mean intima-media thickness (0.07 vs. 0.06; p = 0.035) and 
carotid maximum intima-media thickness (0.09 vs. 0.07; P=0.035) relative to body weight. 
- Infant (6 months)—Increased right atrial area (2.70 vs. 2.50; p = 0.005), right wall thickness 
(3.21 vs. 2.59; p = 0.019), and decreased right ventricular sphericity index (1.82 vs. 1.91; p = 0.010). 
- For systolic function, there was decreased left shortening fraction (29 vs. 36; p < 0.001), mitral 
ring displacement (9.4 vs. 10.8; p < 0.001), tricuspid ring displacement (13.1 vs. 16.3; p < 0.001) 
and increased heart rate (141 vs. 132; p = 0.002). 
- For diastolic function, there was decreased mitral ventricular inflow in early diastole 
displacement time (63 vs. 66; p = 0.014), tricuspid ventricular inflow in early diastole 
deceleration time (52 vs. 62; p < 0.001) and increased isovolumic relaxation time (63 vs. 50;  
p < 0.001). 
- Increased SBP (83 vs. 74; p < 0.001), aortic mean intima-media thickness (1.8 vs. 1.4;  
p < 0.001) and aortic maximum intima-media thickness (2.0 vs. 1.6; p < 0.001) relative to  
body weight. 
[232] 
Nutrients 2015, 7 1400 
 
 
Table 5. Cont. 
Study Type; Population; Year Sample Size (N); Age(s) Cardiovascular Risk Factors Reference 
Retrospective cohort study; 
OMEGA study, VU university 




8–18 year (mean age 12 year) 
Increased SBP and DBP pressure in children conceived through IVF compared to control population 
at a mean age of 12.3 (109 ± 11 vs. 105 ± 10 mmHg, p < 0.001; and 61 ± 7 vs. 59 ±7 mmHg,  
p < 0.001), respectively. 
[233] 
Cross- sectional, case-control 
study; IVF cases-IVF section, 
Department of Obstetrics and 
Gynaecology; University of 
Athens Controls-Aghai Sophia 




Increased SBP and DBP standard deviation score (0.3 vs. −0.3, p < 0.001; 0.7 vs. 0.2 p < 0.001) in 
children conceived through IVF. 
[237] 
Clinical Trial; Swiss children 
IVF and Control siblings of  
IVF children;  




Smaller flow mediated dilation of the brachial artery (6.7 ± 1.6 vs. 8.6 ± 1.7 %; p < 0.0001), faster 
carotid-femoral pulse wave velocity (7.8 ± 2.4 vs. 6.5 ± 1.3 m/s; p < 0.001), increase in carotid  
intima-media thickness (410 ± 30 vs. 370 ± 20 μm; p < 0.0001), higher systolic pulmonary artery 
pressure (39 ± 11 vs. 30 ± 9 mmHg; p < 0.0001) in ART children compared to control children.  
An inverse relationship existed between pulmonary artery pressure and flow mediated dilation  
(r= −0.30, p = 0.001). 
[238] 
ART, assisted reproductive technology; IVF, in vitro fertilization; SBP, systolic blood pressure; DBP, Diastolic blood pressure. 
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6.3. Evidence of Cardiovascular Defects from Animal Models of ARTs 
Animal models of ARTs have been instrumental in providing evidence for further links between 
ARTs and an increased risk of cardiovascular defects (Table 6). 
Table 6. Cardiovascular risk factors from animal models of ARTs. 
Species Age(s) Cardiovascular Risk Factors Reference 
Sheep 
61 day gestation 
125 day gestation 
Increased allometric growth coefficients of heart at 61and 125 days  
of gestation. 
[163] 
125 day gestation 
Increased absolute (25.8 ± 8.9 vs. 19.0 ± 4.1, p = 0.004) and relative heart 
weight (6.5 ± 1.05 vs. 5.7 ± 0.76, p = 0.022) in in vitro embryo culture 
group when serum was supplemented during precompaction period. 
[246] 
125 day gestation 
Inverse relation between heart weight and IGFR2 gene expression  
(r = −0.675, p < 0.001) and loss of methylation of IGF2R in embryo 
culture group when compared to control group. 
[58] 
125 day gestation 
A strong inverse relation between heart weight and IGFR2 gene expression 
in the in vitro embryo culture groups(r = −0.73, p < 0.001). 
[247] 
Cows 
222 day gestation 
(7 months) 
Increased heart girth (56.5 ± 1.2 vs. 52.4 ± 0.9, p = 0.01) and heart weight 
(139.7 ± 8.3 vs. 116.2 ± 5.8, p = 0.02) in embryo transfer and culture 
groups compared to controls. 
[248] 
At birth 
Increased intra-ventricular septum in in vitro produced groups compared to 
embryo transfer group (SOF: 11.8 ± 0.3, Co-culture: 12.0 ± 0.3, embryo 
transfer 10 ± 0.3, p < 0.05) Thicker left ventricular wall during diastole in  
in vitro produced group (co-culture) when compared to embryo transfer 
group (14.5 ± 0.5 vs. 11.8 ± 0.6, p < 0.05). 
[249] 
1 year 
Increased relative heart weight in embryo culture group  
(4.01 ± 0.08 vs. 3.56 ± 0.12, p < 0.02). 
[250] 
Rodents 
21 days after birth Raised SBP in males. [62] 
12–14 weeks  
after birth 
- Higher mean blood pressure during short-term (p = 0.017) and during 
chronic measurements (p = 0.036) in ART mice than in control mice. 
- Impaired acetylcholine-induced vasodilation in the mesenteric arteries 
in ART mice compared with control mice (p < 0.0001). 
- Increased vascular stiffness in ART mice compared to controls 
measured by relationship between inner (p = 0.017) and outer diameter 
(p = 0.033) and carotid pressure in vitro. 
- Impaired acetylcholine-induced vasodilation in vitro (p < 0.0001) and 
increased mean arterial blood pressure in vivo (p < 0.001) was observed 
in the progeny of offspring of ART mate and control female. 
[63,251] 
2 years after birth 
Increased heart weight in embryo culture with serum compared to without 
serum group (0.29 ± 0.02 vs. 0.20 ± 0.01, p < 0.05). 
[54] 
SBP, systolic blood pressure. 
6.3.1. Evidence from Ruminants 
Large Offspring Syndrome (LOS) is a serious side effect in culturing of sheep and cow embryos in 
the presence of serum [252,253] and is associated with an increase in birth weight that persists into 
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postnatal life as well as alterations in the relative growth of organs [252,254]. Culturing sheep zygotes 
in vitro for 5 days in the presence of bovine granulosa cell layers and serum supplementation increased 
the allometric growth coefficients of key organs, including the heart, from as early as 61 days gestation 
and this change persisted to 125 days gestation [163]. Interestingly, the allometric growth coefficient of 
the heart was significantly increased in the fetuses that were cultured in synthetic oviductal fluid media 
that was supplemented with serum, despite no change in body weight at 61 days gestation. However,  
by 125 days gestation, the fetuses were significantly heavier with a higher allometric coefficient of the 
heart [163]. 
Sheep embryos cultured in synthetic oviductal fluid resulted in fetuses with increased heart weight 
compared to embryo transfer controls at 125 days gestation [246]. Furthermore, adding serum to 
synthetic oviductal fluid media during the first 48 h of embryonic development increased relative heart 
weight at 125 days gestation, which suggests that inclusion of serum during the precompaction period is 
more detrimental to the development of the embryo and key organs than the later stages of embryo 
development [246]. Young et al. found that a loss of methylation of insulin-like growth factor 2 receptor 
(IGF2R) was associated with the increased heart weight in the embryo culture groups compared to 
controls [58]. Interestingly, the expression of IGF2R was inversely correlated with heart weight and a 
stronger inverse relationship existed when the analysis was restricted to the embryo culture groups only, 
suggesting that IGF2R plays the role of a clearance receptor for IGF2, and thus decreased IGF2R 
signalling may be responsible for the increase in heart weight because less IGF2 is available to activate 
the IGF1R signalling pathway leading to cardiac growth [247,255,256]. 
Similarly, another study also reported an increased heart girth and weight in an embryo transfer and 
culture group at 222 days of gestation in cows (term, ~280 days) [248]. Another study in cows reported 
an increased intra-ventricular septum in in vitro produced groups (co-culture or synthetic oviductal fluid 
supplementation) and an increased left ventricular wall during diastole at birth in only the in vitro 
produced group (co-culture) when compared to the embryo transfer group (term, ~280 days) [249]. Few 
studies have investigated the impact of embryo culture and transfer on the growth and development of 
the heart in both fetal and postnatal life. However, one study demonstrated that despite normalisation of 
body weight by 1 year of age, the increase in heart weight persisted in the groups where embryos were 
cultured in a nutritional media for 5 days after fertilization [250]. 
6.3.2. Evidence from Rodents 
In vitro embryo culture during the preimplantation period resulted in increased SBP in both male and 
female offspring at 21 days after birth [62]. The gene expression of serum angiotensin converting 
enzyme, which is known to have vasoconstrictive effects through the renin-angiotensin system, was 
upregulated but only in female offspring [62]. Interestingly, there were no changes in the male offspring, 
suggesting that an alternative mechanism may be responsible for the increase in SBP [62]. Endothelial 
dysfunction, higher blood pressure and increased arterial stiffness were found in a mouse model of ART 
at 12–15 weeks after birth [63,251]. The study also found intergenerational effects of ARTs where the 
progeny of ART males and control female had endothelial dysfunction and higher mean blood 
pressure [63,251]. There was also an increase in heart weight in 20 month old mice when the embryos 
were cultured in media containing fetal calf serum [54]. 
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7. What Are the Most Likely Mechanisms Linking ART and Risk of Cardiovascular Disease in 
Fetal and Adult Life? 
7.1. Epigenetic Dysregulation 
Many cardiovascular diseases are known to have an epigenetic origin [179,257]. It has been shown 
that individuals who were exposed to periconceptional undernutrition such as during the Dutch winter 
famine 6 decades ago had an altered methylation profile of imprinted and non-imprinted genes and those 
individuals were also found to have an increased risk of cardiovascular diseases in adulthood [258–260]. 
In animal studies, epigenetic modifications as well as increased prevalence of many cardiovascular risk 
factors such as increased blood pressure, adiposity and insulin resistance were found in the offspring 
exposed to nutritional manipulations during the periconceptional period [59,261]. These findings suggest 
that epigenetic dysregulation could be a plausible mechanism that links ARTs with increased risk factors 
for cardiovascular diseases [262]. 
A series of studies have identified an association between ARTs and epigenetic disorders [95,263]. 
Children with Beckwith-Wiedemann syndrome, which is caused by an imprinting disorder, are 3–14 
times more likely to be conceived by ARTs [264–267]. Molecular analysis in these studies showed 
hypomethylation of maternal copy of KCNQ1 overlapping transcript 1 (KCNQ1OTI), an antisense RNA 
normally expressed from the paternal allele and located at one of the differentially methylated regions 
(DMRs) of chromosome 11p15 [264–269]. Studies have also found hypermethylation of HI9, which  
is located at another DMR of chromosome 11p15, as well as hypomethylation of mesoderm-specific 
transcript homolog protein (MEST), small nuclear ribonucleoprotein N (SNPRN), pleiomorphic adenoma 
gene-like 1 (PLAGL1) in ART children with Beckwith-Wiedemann syndrome [264,268,269]. There  
are also reports of other imprinting defects such as Angelman syndrome, Retinoblastoma, Prader–Willi 
syndrome and Russell–Silver syndrome in children conceived through ARTs [270,271]. At the blastocyst 
stage, IVF resulted in aberrant H19 methylation in humans and mice [226,272]. Large offspring syndrome 
LOS is a frequent occurrence in livestock conceived through ARTs and is also caused by loss of 
methylation in the maternal DMR of IGF2R, which is an imprinted gene [58]. 
A study investigating the DNA methylation levels of more than 700 genes (1536 CpG sites) in the 
placenta and cord blood reported lower mean methylation at CpG sites in the placenta and higher mean 
methylation at CpG sites in cord blood from 10 children conceived in vitro compared to 13 children 
conceived naturally. Upon examining the gene expression levels of a subset of genes that had altered 
methylation levels, CCAAT/enhancer-binding protein alpha (CEBPA) in cord blood and CEBPA, 
MEST, neuronatin (NNAT) and serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment 
epithelium derived factor), member 1(SERPINF1) in placenta had significant difference in mean 
transcript levels [273]. Interestingly these genes are known to be associated with adipocyte development 
and differentiation, insulin signalling and/or obesity [274–277]. 
Increased methylation of the imprinted genes H19, glucosyltransferase 2 (GTL2) and decreased 
methylation of paternally-expressed gene 3 (PEG3) were found in the aorta, but not in the liver of the 
mice conceived through ART [251]. This alteration of the methylation levels was transmitted to the next 
generation with levels comparable to the methylation of the parent generation [251]. Interestingly, the 
altered methylation levels were restored in ART mice and in its progeny with the administration of 
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butyrate (a histone deacetylase inhibitor) [251]. As previously mentioned, the study also found vascular 
dysfunction and arterial hypertension in ARTs mice and its offspring. Consistent with this finding,  
the study reported an increased DNA methylation of the promoter of the eNOS gene in the aorta of the 
ARTs mice, which is an important regulator for systemic vascular function [251]. This increased 
methylation level resulted in decreased eNOS mRNA expression in the vasculature and lower levels of 
nitric oxide in the plasma of ARTs mice [251]. In addition, butyrate administration to ARTs mice also 
normalized DNA methylation of the promoter of the eNOS gene, eNOS mRNA expression and plasma 
nitric oxide concentration [251]. 
These altered methylation levels provide strong evidence for epigenetic dysregulation as a result of 
ARTs, which could possibly affect the expression levels of genes involved in cardiovascular regulation 
as well as other major regulatory pathways increasing the risk of long-term diseases in adult life [63]. 
These alterations in epigenetic mechanisms may stem from several steps involved in ARTs such as 
ovarian stimulations and in vitro embryo culture (Figure 3). Studies have investigated the impact of these 
steps separately, which may underpin the source for epigenetic dysregulations [163,278,279]. 
7.1.1. Ovarian Hyperstimulation/Superovulation 
Superovulation occurs during meiosis of oocyte development/maturation when the oocytes are still 
acquiring imprinting marks and may lead to imprinting defects. In humans, studies have reported 
hypomethylation of the KCNQ1OT1 DMR (KvDMR1) in the germinal vesicle and metaphase I stage as 
well as hypomethylation of KCNQ1OT1 in the metaphase II stage of the superovulated oocytes, which 
suggests that ovarian hyperstimulation may result in the release of immature or young oocytes that have 
not undergone complete methylation, including the establishment of appropriate imprinting [85,280]. 
Imprinting errors have been found in H19 and MEST in metaphase II oocytes after ovarian stimulation, 
however, it could not be determined whether alterations in the methylation patterns of these genes were 
associated with the superovulation process itself or the age and infertility status of the patients [281]. 
There is evidence that superovulation can affect the quality of the embryo as well as the uterine milieu, 
and these factors can indirectly affect the epigenetic status of the oocyte [48]. 
In animal studies where infertility is not a confounding factor, an abnormal methylation pattern at the 
2 cell stage was found in the embryos from superovulated mice using immunofluorescent staining [282]. 
Downregulation of candidate reprogramming genes which are involved in base excision repair proteins 
such as APEX nuclease (multifunctional DNA repair enzyme) 1 (APEX1), polymerase (DNA directed), 
beta (POLB) and the 5-methyl-CpG were found at the morula stage of the mouse embryo after 
superovulation and suggests that superovulation may also hamper the maintenance of imprinting [278]. 
In line with this finding, lower protein expression levels of APEXI were observed in both early and late 
morula stages and the level of protein expression correlated the mRNA expression levels [278]. Loss of 
methylation of SNRPN, KCNQ1OT1 and PEG3 in the blastocyst stage was also observed in a  
dose-dependent manner with higher doses of hormones resulting in greater imprinting disturbances [283]. 
Superovulation in mice decreased the methylation levels of H19 and significantly increased the methylation 
levels of PEG1 and SNRPN imprinted genes in the sperm of the offspring in both the first and second 
generation [53]. Together these data suggest that changes in global methylation may account for 
spontaneous embryo loss and developmental failure, while locus-specific epigenetic errors may result in 
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defined phenotypes associated with genomic imprinting disorders; thereby suggesting that oocytes from 
superovulated animals may have a reduced ability to complete the global reprogramming necessary for 
proper development [282,284]. 
7.1.2. In Vitro Embryo Culture 
In vitro embryo culture occurs during the sensitive period of maternal and paternal demethylation  
and remethylation and thus may affect the maintenance of genomic imprinting during this process [285]. 
There is evidence of abnormal methylation, mainly due to embryo culture, as a result of the IVF procedure 
in mice [286]. For example, embryo culture of preimplantation mouse embryos using Whitten medium 
resulted in biallelic expression and loss of methylation of the H19 gene [287]. Similarly a greater loss of 
methylation was observed in H19 after embryo culture in M16 medium than in G1/G2 medium [287]. 
There were also differences in the gene expression of 114 genes in the preimplantation embryos of the 
mice cultured in Whitten culture medium and 29 genes when cultured in KSOM + AA [61]. Biallelic 
expression of the imprinted gene H19 was found in the placenta which persisted till mid gestation when 
the embryos were cultured in whitten or KSOM + AA medium [288]. There is also evidence of perturbed 
gene expression after embryo culture [163]. Increased expression of the imprinted genes, IGF2 and H19 
and growth factor receptor binding protein 10 (GRB10), along with increased methylation of H19 and 
decreased methylation of growth factor receptor binding protein 7 (GRB7) were observed in  
fetuses that had undergone preimplantation embryo culture in M16 medium with fetal calf serum 
supplementation [61]. In vitro culture with serum supplementation also resulted in hypomethylation of 
IGF2R associated with LOS in ruminants [58]. It has been speculated that culture media procedures may 
induce abnormal methylation at imprinted loci by facilitation the removal of methyl groups from 
cytosine bases or interfering in normal gamete development which may lead to incomplete imprint 
erasure and/or reestablishment of methylation pattern [95,285]. The methionine content of the media 
may also affect DNA methylation and imprinting [102,289]. 
These findings provide substantial evidence that in vitro embryo culture can impair epigenetic 
mechanisms. Studies investigating epigenetic dysregulation associated with both ovarian stimulation and 
embryo culture found that defects in imprinting were neither observed in all the embryos nor at every 
imprinting locus. Some loci were affected more than others. Hence, more studies are required to 
understand the stochastic nature of these imprinting defects. 
7.2. Impaired Gastrulation 
Early interaction between the embryo and the endometrium is critical for proper development and 
implantation of the embryo [290,291]. This in turn determines proper gastrulation and organogenesis. 
Embryo cultured in media in vitro lacks these early interactions and the exchange of factors between 
embryo and endometrium. This can alter the timing of expression of Hox genes, which control the body 
plan of an embryo along the anterior-posterior (head-tail) axis [292,293]. In addition, studies have shown 
that culture of the embryo in vitro affects the proper differentiation of the inner cell mass, which are 
precursors of ectoderm and endoderm (germ layers formed during gastrulation) [294,295]. These two, 
individually or in combination, can alter gastrulation and subsequently organogenesis. It is reasonable 
to speculate that organogenesis of the heart, which is the first organ to form, may be affected by procedures 
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involved in ARTs and abnormalities in heart development are known to cause congenital defects and 
other cardiovascular disorders (Figure 3) [296]. 
 
Figure 3. Diagrammatic representation of the possible links between ARTs and cardiovascular 
disorders [284,293,297] 
8. Conclusions 
This review summarises the literature showing that ARTs are associated with an increased risk of 
cardiovascular disease. Many studies have been conducted that have shown an association between 
ARTs and congenital heart defects. It is clear from the available evidence that the association is not 
restricted to a specific type of ARTs. However, a major gap of literature exists in terms of our 
understanding of the long-term effects of ARTs in childhood and adulthood. Some follow-up studies 
have confirmed these findings in children of ARTs in the fetal and neonatal periods. Given the young 
age of the ART population, it is necessary to perform life course studies that will provide valuable 
evidence not only to ensure better medical diagnostics and care for these children but also to call for 
more studies to pinpoint the mechanistic alterations that are responsible for ARTs induced cardiovascular 
risk factors. Understanding the important events that occur during the developmental periods when ARTs 
procedures are applied have identified mechanisms underlying the link between ART and an increased 
risk of cardiovascular defects in the embryonic period and cardiovascular disease in postnatal life. 
Epigenetic alterations have emerged as a key mechanistic alteration that can predispose an increased 
risk of cardiovascular disorders in the ART population. A major challenge is to isolate the effects of 
infertility of the parents that sought ARTs procedures and may render epigenetic alterations in the offspring. 
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In this regard, many animal models of ARTs have been a major source of evidence suggesting the effects 
of ARTs procedures on cardiovascular dysfunctions and epigenetic alterations. This warrants further 
studies to pinpoint specific epigenetic alterations that directly link to the development of cardiovascular 
disease in later life. Consequently, a genome-wide epigenetic profiling of children conceived through 
ARTs during the embryonic stages can be used as a tool to identify embryos that carry epigenetic 
alterations linked to the development of cardiovascular disease in adult life. Furthermore, epigenetic 
profiling can also be conducted in both neonatal and adult life, to identify individuals with a higher risk 
of developing cardiovascular disease in later life. 
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